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INTRODUCTION 
 In recent years, there has been increasing evidence which shows strong 
links between inflammation and the pathogenesis of atherothrombotic stroke. 
Acute phase proteins have been implicated to play roles both during acute 
and chronic inflammatory processes in different diseases including ischemic 
stroke1. Even low grade infections may cause elevation of various acute 
phase reactants which may partly be responsible for the inflammatory process 
observed in atherosclerotic lesions, which may inturn relate to occurrence of 
ischemic symptoms2. 
 Inflammation plays a major role in atherothrombosis and measurement 
of inflammatory markers such as C–Reactive Protein, an acute phase reactant 
that reflects low-grade systemic inflammation has been studied in a variety of 
cardiovascular diseases3. There is growing evidence of the prognostic 
importance of CRP in ischemic stroke4. Also CRP has been found to be a 
strong but relatively non-specific risk factor of fatal stroke in elderly 
persons5. 
 CRP, a sensitive meter of inflammation, induces vascular thrombosis 
by stimulating monocytes to express tissue factor, the initiator of the extrinsic 
pathway of coagulation6. Elevated levels of CRP are found to be related with 
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higher risk of first-ever cardiovascular, cerebrovascular and peripheral 
vascular diseases7. 
 The WHO has recently set international reference standard for the use 
of highly sensitive CRP assays. This has enhanced the usefulness of CRP as a 
reliable predictor of cardiovascular events.  
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AIM 
1. To evaluate the predictive value of hs-CRP in relation to the ultimate 
functional outcome in first ever ischemic stroke after 4 weeks. 
2. To correlate the hs-CRP levels with various cardiovascular risk factors. 
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REVIEW OF LITERATURE 
Stroke: 
 Stroke or cerebrovascular accident is defined as a rapidly developing 
clinical symptoms and or signs of focal and at times global (applied to 
patients in deep coma) loss of cerebral function with symptoms lasting more 
than 48 hours or leading to death with no apparent cause other than that of 
vascular origin. 
Table 1: Pathologic Classification of Stroke 
Pathologic type8 Percentage (%) 
Cerebral Infraction 
 Large vessel occlusion 
 Small vessel occlusion 
 Cardiac emboli 
 Hematological disorders 
80% 
Primary intracerebral hemorrhage 
 Hypertensive bleeding 
 Vascular malformations 
 Bleeding diathesis 
 Anticoagulants 
10% 
Non traumatic SAH 
 Aneurysm 
 Vascular malformation 
 Non-aneurysmal SAH 
5% 
Other causes 5% 
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CAUSES OF CEREBRAL ISCHEMIA AND INFARCTION9 
• Arterial Wall disorder 
• Atherthromboembolism 
• Intracranial small vessel disease (lipohyalinosis, microatheroma), 
• Trauma 
• Dissection 
• Fibromuscular dysplasia 
• Congenital arterial anomalies 
• Moya Moya syndrome 
• Embolism from arterial aneurysm 
• Inflammatory vascular disease 
• Binswanger disease 
• Irradiation, infection     
• Embolism from the heart 
• Hematological disorders 
• Miscellaneous: 
Pregnancy 
OCP 
Drug Abuse 
Cancer 
Migraine 
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Inflammatory Bowel Disease 
Homocystinemia 
Fabry’s disease 
Mitochondrial Cytopathy 
Hypercalcemia 
Hypoglycemia 
Epidermal nevus syndrome 
Fat embolism 
Thus it is evident that  
1) Cerebral infraction accounts for 80% of all strokes. 
2) Atherothromboembolism of cerebral arterial supply is the cause in 
 about 50% of the cases of cerebral infarction 
ATHEROSCLEROSIS 
 Atherosclerosis is a disease primarily of the elastic arteries (eg:aorta, 
carotid, iliac arteries) large and medium sized muscular arteries (eg:coronary 
and popliteal arteries). Laboratory and clinical evidence has demonstrated 
that atherosclerosis is not simply a disease of lipid deposits. Rather, systemic 
inflammation also plays a pivotal role in atherothrombotic inception and 
progression10,11,12. Mononuclear cells, macrophages, and T lymphocytes are 
prominent in atheromatous plaques in the arterial wall13,14,15,16. Furthermore, 
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the shoulder region of a plaque, the most vulnerable site for rupture in acute 
coronary syndromes, is heavily infiltrated with inflammatory cells17,18,19. 
Cytokines, which cause the de novo hepatic production of acute phase 
reactants such as C-reactive protein20, have been shown to increase in acute 
coronary syndromes even in the absence of myocardial necrosis21. Therefore, 
CRP has been examined as a surrogate marker of other inflammatory 
mediators such as interleukin-6 and tumor necrosis factor-  to understand 
better the inflammatory component of atherosclerosis22,23. Current knowledge, 
however, suggests that the CRP concentration might reflect the vulnerability 
of the atheromatous lesion and the likelihood of a plaque to rupture11,12,24. 
This acute phase reactant has been studied over the last several years in a 
wide variety of atherosclerotic diseases21,25,26,27,28,29. Its prognostic utility in 
acute coronary syndromes21,25,26,27,28,29 and its ability to predict future 
coronary events in apparently healthy men and women30,31,32,33,34,35,36,37,38,39 
have been demonstrated. The development of high sensitivity CRP (hs-CRP) 
assays has been instrumental in exploration of the role of this acute phase 
reactant in predicting first cardiovascular  and cerebrovascular events. 
RISK FACTORS FOR STROKE 
 Since stroke is a multifactorial disease, both genetic and environmental 
risks affect the disease.  
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1. Age and gender: 
 Stroke incidence increases with age. With each decade after 55 years, 
the risk doubles. Approximately 80% of strokes  occur in the elderly. Gender 
also affects the risks. Men develop strokes at a higher rate than women up to 
the age of 7540.  
2. Smoking: 
 Cigarette smoking is a well established risk factor for ischemic 
stroke41,42. A meta-analysis has shown a 50% increase in stroke risk for 
smokers43.  
3. Diabetes Mellitus: 
 Diabetes mellitus increases stroke risk to 2 to 4 fold compared to non-
diabetes subjects while also increasing mortality and morbidity after stroke. 
4. Hypertension: 
 Hypertension is the single most important modifiable risk factor for all 
strokes accounting for up to 50% of all strokes44. 
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5. Hypercholestrolemia: 
 Both elevated total cholesterol as well as low density lipoprotein 
increases the risk of CHD and stroke. 
6. Homocysteinemia: 
 Homocysteinemia has been described as a possible risk factor for 
ischemic stroke. Presumed mechanism is increased stress tolerance of the 
endothelium, thrombosis, inflammation and oxidative stress45. 
7. Inflammation and bio-markers: 
 Inflammation as part of atherosclerotic pathway has been implicated in 
cardiovascular disease and ischemic stroke. Inflammatory biomarkers such as 
CRP, IL-6 and heat shock proteins have been shown to  be elevated in acute 
ischemic stroke46,47,48,49,50,51,52,53. 
8. Evidence of existing vascular disease:  
 Myocardial infarction 
 Cardiac failure 
 Atrial fibrillation 
 Peripheral vascular disease 
 Transient ischemic attacks 
 Carotid arterial bruit and stenosis 
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9. Miscellaneous9,54 :   
 Plasma fibrinogen 
 OCP 
 Alcohol 
PREDICTORS OF STROKE OUTCOME 
I) Demographic factors: 
1. Age: 
 Age is one of the major factors that negatively influence the outcome 
for patients with ischemic stroke55. Older patients are less likely to recover 
than younger patients with similar sized infarcts.  
2. Gender: 
 Some studies have shown male sex associated with poorer outcome56 
whereas other studies have shown no difference. The explanation for this may 
be hormonal. Estrogen seems to be an important mediator of improved 
outcome after ischemic brain injury. 
3. Race/Ethnicity: 
 Although it is well understood that the incidence of stroke varies 
among races and ethnicities, there is no significant difference in the outcome 
between groups57. 
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II) Cerebrovascular risk factors: 
1. Previous stroke and atrial fibrillation: 
 Strokes in patients with previous stroke and atrial fibrillation are 
usually more severe, more disabling and associated with a higher moratlity. 
III) Clinical findings: 
1. Level of consciousness and gaze deviation: 
 Initial level of consciousness is an important predictor with decreased 
level of consciousness predicting poor outcome58. The presence of gaze 
deviation is associated with poor outcome. 
2. Blood Pressure:  
 Abnormal blood pressure may influence outcome. Clinical studies of 
blood pressure reduction have shown a decrease in cerebral blood flow to the 
infracted area59. On the contrary, excessively elevated blood pressure has 
negative long term effects on blood brain barrier function. 
3. Temperature: 
 For each one degree celsius increase in body temperature, the relative 
risk of poor outcome rises two fold60. This may be due to the increased 
concentration of excitotoxic neurotransmitters present. Elevated temperature 
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(>37.50C) was an independent predictor of large volume infarct and higher 
neurological deficit when it occurred in the first 24 hours after first stroke 
onset. 
IV) Laboratory findings: 
1. Glycine and glutamate: 
 High glycine or glutamate levels strongly correlated with large infarct 
size and severe neurological deficits61. 
2. S-100: 
 Increased serum levels of S-100 correlate with neurologic outcome. 
3. Neuron-specific enolase:   
 This enzyme has been shown to increase in acute stroke. 
4. Serum Glucose: 
 Hyperglycemia is associated with increased morbidity and mortality62. 
Hyperglycemia seems to produce its detrimental effects by causing a 
profound cellular acidosis. Clinical studies have shown an association 
between hyperglycemia and cerebral edema62. 
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PROGNOSTIC VALUE OF ACUTE PHASE REACTANTS (APR) 
1. Erythrocyte Sedimentation rate (ESR): 
 Elevated ESR predicts poor outcome63. 
2. C-reactive protein (CRP): 
 CRP concentrations measured within 72 hours of stroke independently 
predicted survival after ischemic stroke. Patients with levels above 10.1 mg/L 
had significantly worst survival64. 
C REACTIVE PROTEIN 
History and nomenclature: 
 CRP was originally discovered by Tillet and Francis in 1930 as a 
substance in the serum of patients with acute inflammation that reacted with 
C-polysaccharide of Pneumococcus65. It is a 23- KDa protein65. 
Genetics and Biochemistry: 
 The CRP gene is located on the first chromosome (1q21-q23).CRP is a 
224 residue protein with a monomer molar mass of 25106 Da and native 
cyclic pentamer mass of 125530.  
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Function:  
 CRP is a member of the class of acute phase reactants. It is thought to 
assist in complement binding to foreign and damaged cells and affect the 
humoral response to disease. It is believed to play an important role in innate 
immunity, as an early defense system against infection.  
Diagnostic Use: 
 CRP is used mainly as a marker of inflammation. Measuring and 
charting CRP values can prove useful in determining disease processes or the 
effectiveness of treatment. 
CRP and Atherosclerosis: 
 Accumulating data suggest that arterial tissues can produce CRP, with 
CRP and complement m-RNA being substantially upregulated in 
atherosclerotic plaque11. Thus CRP may serve as an endogenous activator of 
complement in atheroma. 
Dynamics of CRP: 
 The acute phase response comprises the non-specific physiological and 
biochemical responses of endothermic animals to most forms of tissue 
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damage, infection, inflammation and neoplasia. In particular the synthesis of 
a number of protein is upregulated principally in hepatocytes under the 
control of a cascade of cytokines, including interleukin-1, tumour necrosis 
factor-α and interleukin-6 originating at the site of pathology. 
 CRP levels rapidly rise after an inflammatory stimulus and depending 
on the intensity of the stimulus, even as several 100 fold increase in plasma 
levels may occur66. CRP is not consumed to a significant extent in any 
process and its clearance is not influenced by any known condition. Therefore 
its concentration appears to be dependent on the rates of production and 
excretion. The long half life of CRP approximately 19 hours, makes it's 
detection in blood easy even several hours after acute stimulus. Because of all 
these characters, CRP can be called as an “ideal marker of inflammation”.  
CRP VS OTHER ACUTE PHASE PROTEINS 
 The group of acute phase proteins includes, besides CRP, many other 
proteins, such as Serum Amyloid A (SAA), fibrinogen, pro-calcitonin, 
haptoglobin, alpha 2 haptoglobin, alpha 1 acid glycoprotein, ceruloplasmin, 
alpha 1 anti-trypsin and albumin. 
 The disadvantage of haptoglobin, alpha 2 haptoglobin, alpha 1 acid 
glycoprotein, ceruloplasmin, alpha 1 anti-trypsin and albumin is that the 
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difference between normal and pathological values are very small. The values 
measured in pathological conditions are only a few times those found in 
healthy individuals, and they are also determined by other (ex: nutrional) 
factors in addition to infections.  
 Determination of SAA is totally cumbersome because of lack of 
methods for routine measurements. Compared to many other acute phase 
proteins, CRP has the advantage that pathological values are easy to detect 
since the increase in concentration can be several 100 fold. 
 Hepatocyte CRP is triggered by cytokines such as IL-1, IL-6 and 
tumour necrosis factor secreted by monocytes, macrophages. The elevation of 
IL-6 concentration in serum is one of the earliest markers of inflammatory 
processes, detectable 2 to 3 hours after onset of infection. Similarly IL-6 
concentration is normally detectable 4 to 7 hours later depending on the 
sensitivity of the assay. 
HIGH SENSITIVITY CRP (hs-CRP) 
 In the late 1990s, high sensitivity CRP assays became available, 
allowing assessment of serum concentrations at the lower end of its 
distribution. In the subsequent years, hs-CRP levels far beneath the cutoff 
value, indicative of an immediate-phase response, predicted the risk of 
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cardiovascular, cerebrovascular disease, diabetes mellitus, and cognitive 
impairement 67,68,69,70. 
Normal reference range:    0.02 to 8.0 mg/L 
ROLE OF ACUTE PHASE REACTANTS IN ACUTE ISCHEMIC 
STROKE 
 Inflammatory factors play an important role in the pathogenesis of 
ischemic stroke. Acute phase proteins level such as a fibrinogen, CRP, 
ferritin increase after acute ischemic stroke. These findings support a possible 
role of an inflammatory stimulus in the acute ischemic stroke. 
Fibrinogen: 
 In acute phase of cerebrovascular diseases, biochemical markers of 
inflammation could be useful to predict severity of stroke71. Fibrinogen is a 
well known acute phase protein and risk factor for myocardial infarction and 
stroke. High fibrinogen levels represent an acute phase response in early 
acute stroke72. 
 Fibrinogen is involved in primary haemostasis, platelet aggregation, 
and leukocyte-endothelial cell interactions and is the major determinant of 
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whole blood and plasma viscosity73. Fibrinogen levels increase after an acute 
stroke 74. 
Ferritin: 
 There are some evidences about the significant role of iron (Fe+2) in 
cerebral damage75. The role of iron in acute ischemic stroke has been 
investigated; as a result of this research, there may be relationship between 
high iron level and poor prognosis74. 
 It is suggested that high serum ferritin levels within the first day of 
hospitalization for an acute ischemic stroke are related to poor prognosis75. 
Oxidative metabolism during ischemic stroke together with high iron content 
in the brain synergise to increase the oxidative damage. High plasma ferritin, 
as a measurement of iron stores, and high cerebrospinal fluid ferritin have 
been related to poor outcome in stroke patients76. Serum ferritin level and 
large size of lesion were independently associated with mortality. Increased 
serum ferritin levels correlate to severity of stroke and the size of the lesion77. 
CRP: 
 High levels of hs-CRP are associated with adverse cardiovascular and 
cerebrovascular events. High CRP predicts the risk of carotid stenosis; first 
stroke and post stroke mortality. 
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CRP AND CORONARY EVENTS 
 In patients with established coronary disease, CRP has been shown to 
predict adverse clinical events. In addition, prospective studies have 
consistently shown that CRP is a strong predictor of future coronary events in 
apparently healthy men and women. The relative risk associated with CRP is 
independent of other cardiovascular disease risk factors. High sensitivity CRP 
(hs-CRP) assays are needed for risk assessment of cardiovascular disease. 
CRP AND ISCHEMIC STROKE 
 Elevated plasma CRP concentrations are also associated with an 
increased risk of cerebrovascular events and an increased risk of fatal and 
nonfatal cardiovascular events in ischemic stroke patients78. Determination of 
plasma CRP concentrations could be used as an adjunct for risk assessment in 
primary and secondary prevention of cerebrovascular disease and be of 
prognostic value. CRP is as an independent predictor of cerebrovascular 
events in at-risk individuals and ischemic stroke patients. 
FRAMINGHAM STUDY: 
 To address the baseline CRP level and the risk of subsequent stroke 
events, the measurement of CRP was done in the Framingham study original 
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cohort who were free of stroke or TIA at the time of their 1980 to 1982 
clinical examination and related the baseline CRP plasma generation to the 
incidence of first stroke or TIA in these subjects during a 12 to 14 years 
follow up – men with the higher baseline CRP values had twice the risk of 
ischemic stroke and women with highest CRP level had a 5-fold increase in 
risk of any vascular event and a 7-fold increase in risk of the comorbid 
outcome of myocardial infarction or stroke. The data derived from this study 
demonstrated a graded increase in the incidence of ischemic stroke and TIA 
with increased levels of CRP79. 
RELATIONS OF hs-CRP TO VARIOUS CARDIOVASCULAR RISK 
FACTORS 
 There is increasing evidence that higher levels of hs-CRP is a predictor 
of cardiovascular disease (CVD), and may play an important role in the 
different stages of the development of atherosclerosis3,38. 
 In healthy subjects even a moderate increase of hs-CRP within the 
normal range (hs-CRP <5 mg/L) is considered to be predictive for a variety 
of cardiovascular events, independent from other cardiovascular risk 
factors3,38,80. 
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 Increased CRP levels showed statistically significant positive 
correlations with other established risk factors including age, number of 
cigarettes smoked per day, body mass index, systolic and diastolic blood 
pressure, total cholesterol, triglycerides, homocysteine, fibrinogen, and  
D-dimers; CRP levels are correlated inversely with exercise frequency and 
high density lipoprotein cholesterol (HDL-C)81. CRP has emerged as a 
strong, independent risk factor in its own right. 
 A study was performed by So Yeon Ryu and his colleagues to evaluate 
the relation of high sensitivity C-reactive protein  with several cardiovascular 
risk factors such as age, blood pressure, smoking habit and serum lipids, body 
mass index, blood glucose, regular exercise, alcohol drinking, white blood 
cell counts in a cross-sectional survey82. Plasma hs-CRP was measured by 
immunoturbidimetry in 202 subjects, aged over 50 years, who participated  in 
health-check survey in a rural area of Jeollanamdo, Korea. Plasma hs-CRP 
level was 1.9 ± 3.0 mg/dL. He concluded that there were significant 
associations between hs-CRP levels and age, white blood cell counts, blood 
glucose, diastolic blood pressure, HDL-cholesterol, body mass index and 
smoking status. Although the correlation between plasma hs-CRP and HDL-
cholesterol was negatively significant, other blood lipid profile, such as total 
cholesterol, triglyceride and LDL-cholesterol did not significantly correlate 
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with hs-CRP. Smoking is well supposed to give chemical and oxidative 
stimuli to the cardiovascular system and cause inflammation83. It has recently 
been reported that moderate alcohol consumptions reduces circulating CRP84. 
But in his study, the plasma hs-CRP level was not significantly affected by 
the alcohol drinking. 
 Increased intima-media thickness of the common carotid arteries and 
elevated levels of  hs-CRP  are both shown to be associated with the 
occurrence of stroke85. This was shown in a study conducted by Gulcin 
Benbir and his colleagues. He studied the relationship of elevated hs-CRP 
levels with the extent of carotid atherosclerosis . He studied 104 patients aged 
between 30 to 92 yrs with acute ischemic stoke. The hs-CRP determination 
was performed within 72 hours after admission. The relationship between the 
hs-CRP level and the other risk factors were also evaluated in his study. All 
of the variables except HDL levels, failed to show a significant relationship 
with the hs-CRP levels. Only variable that showed a significant relation with 
the levels of the hs-CRP was HDL levels. It was shown that the major risk 
factors of the stroke were also associated with the higher levels of CRP83  and 
the treatment with antiaggregants and statins might have lowered the levels of 
CRP through their regulatory effects on the inflammation86,87. 
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 High blood pressure, as well as triglycerides, HDL cholesterol and 
diabetes were found to be strongly associated with CRP in a study by 
Blackburn R. et al., (2001)88. 
 In a study by Choi H. et al., 2004, there was no association between 
hs-CRP and carotid atherosclerosis in subjects with hypertension and 
normotension89. 
 Smokers had higher WBC, fibrinogen, and CRP levels in a study by 
Magyar et al. (2003)90. Several CHD risk factors appear to modulate the 
inflammatory response and affect hs-CRP concentration. Cigarette smoking 
has also been shown to increase the concentration of several inflammatory 
markers, including hs-CRP, interleukin-6, and soluble intercellular adhesion 
molecule-13. Increases of both interleukin-6  and soluble intercellular 
adhesion molecule-1  were shown to be associated with increased risk of 
future first coronary events in both men and women. Smoking cessation 
decreases these markers. 
 Diabetic patients are reported to have increased hs-CRP values91; In 
this regard, links between hs-CRP and the insulin resistance syndrome have 
also been reported . In addition, experimental findings suggest that increased 
blood pressure promotes endothelial expression of cytokines and 
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inflammatory activation15. These observations suggest that perhaps better 
control of diabetes and hypertension may attenuate the contribution of the 
inflammatory response to overall cardiovascular risk. Taken together, the 
available evidence thus supports the hypothesis that hs-CRP concentrations 
correlate with endothelial dysfunction .  
 Also , another study by Liuzzo et al21 showed that in  patients with 
severe unstable angina, hs-CRP concentrations >3 mg/L at admission were 
associated with an increased incidence of recurrent angina, coronary 
revascularization, MI, and cardiovascular death. 
 In a similar study of unstable angina, Ferreiros et al27 concluded that 
the prognostic value of hs-CRP in predicting adverse outcome at 90 days.  
 A recent report by de Winter et al26 showed that hs-CRP concentrations 
>5 mg/L at admission in 150 patients with non-ST-elevation acute coronary 
syndromes were associated with an increased incidence of major cardiac 
events within 6 months .  
 Results from a population-based study in Russia The Arkhangelsk 
study conducted by M. Averina and his colleagues revealed U-shaped 
association between hs-CRP and total alcohol intake92. This U-shaped 
 25
association became non-significant in both sexes after adjustment for age, 
BMI, smoking status, diabetes mellitus and cardiovascular medication. 
 Another study conducted by Chrysohoou et al in 2003, showed a  
U-shaped relation of several biochemical parameters related to 
atherosclerosis including hs-CRP and the amount of alcoholic beverages 
consumed93. 
 A study by Rasouli Mehdi et al in 2006 , showed that elevated hs-CRP 
was assosciated with male sex, diabetes, hypertension and high levels of 
serum glucose94. 
 Another study by Minna Soinio et al concluded that diabetic patients 
have higher levels of hs-CRP than people without diabetes and that elevated 
hs-CRP levels are an independent risk factor for death from CHD in people 
with diabetes95. 
PROGNOSTIC INFLUENCE OF CRP LEVELS AFTER FIRST EVER 
ISCHEMIC STROKE 
 There is growing evidence of the prognostic importance of C-reactive 
protein in ischemic stroke. However, the independent value of CRP at 
different stages after stroke has not been established. Di Napoli and his 
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colleagues did a study to compare the relation of CRP at admission and 
discharge with 1-year outcome96 One hundred ninety-three patients were 
included in the study. Serum CRP was measured within 24 hours after index 
ischemic stroke, within 48 to 72 hours, and at hospital discharge. He 
examined the association between the level of CRP at different stages after 
stroke and outcome. A cutoff point of 15 mg/L for CRP at discharge provided 
optimum sensitivity and specificity for adverse outcome, based on the 
receiver operator curves. He concluded that CRP is a marker of increased  
1-year risk in ischemic stroke. CRP at discharge is better related to later 
outcome and could be of greater utility for risk stratification. These findings 
are consistent with the hypothesis that elevated CRP may predict future 
cardiovascular events or death. 
  Mario Di Napoli and his colleagues also conducted a study on the role 
of CRP levels in short term prognosis after first ever ischemic stroke. About 
30 ischemic stroke patients between the ages of 49 and 90 yrs of age were 
studied within four weeks of occurrence of the first ever cerebrovascular 
ischemic events. CRP levels were collected within a media of 14 days from 
the stroke onset. It was found that patients with the highest CRP levels  
(> 5mg/L) at  study  died early or had severe complications  after  stroke  or  
had no  evidence   of recovery during the two  month follow up97. This study 
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concluded that CRP was increased in patients with cerebral ischemia, the 
higher levels correlating with significant neurological defecit and disability 
and appears to provide additional information regarding prognosis after 
ischemic stroke as it appears to do after myocardial infarction. 
 Kocer A and his colleagues did a study to evaluate serum hs-CRP 
levels in ischemic stroke patients and in a control group, and to correlate the 
values with other generally known risk factors98. A total of 47 patients with 
ischemic stroke and 26 control subjects were recruited. Peripheral blood 
samples from stroke patients were obtained between 12-24 hours after the 
stroke. It was found that the mean serum levels of hs-CRP were significantly 
higher in patients  than controls. Also the level of hs-CRP was above the risk 
limit in 39 patients (83.0%) and 7 controls (26.9%). The hs-CRP values were 
not related to the presence of other vascular risk factors, except for 
cholesterol level. In this study the correlation analysis of hs-CRP revealed a 
linear correlation with death within six months and the presence of 
hypertension. 
 Another study conducted by Winbeck K and his colleagues 
investigated the impact of early serial CRP measurements in hyperacute 
ischemic stroke on long-term outcome99. One hundred twenty-seven 
consecutive patients without thrombolysis with a first ischemic stroke no 
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more than 12 hours after symptom onset were examined. Serial CRP 
measurements were done at admission (CRP 1), within 24 hours (CRP 2), and 
within 48 hours (CRP 3) after symptom onset. In addition to several 
cerebrovascular risk factors, the 1-year outcome and the lesion volumes of 
initial diffusion-weighted images were determined.  The CRP level measured 
within 12 hours after symptom onset of an acute ischemic stroke was not 
independently related to long-term prognosis. In contrast, a CRP increase 
between 12 and 24 hours after symptom onset predicted an unfavorable 
outcome and was associated with an increased incidence of cerebrovascular 
and cardiovascular events. 
 Ufuk Emry and his colleagues conducted a study to determine the 
influence of fibrinogen, CRP and other acute phase reactants in acute 
ischemic stroke in acute period (first 24 to 72 hours)100. Forty-three patients 
(23 female, 20 male) who have been diagnosed as acute ischemic stroke, in 
Neurology department of Ankara Hospital, between June 2001 and December 
2001 were included in this study. He concluded that the fibrinogen and CRP 
have a close relationship as inflammatory markers in the acute phase of 
ischemic stroke. In this study, which supports the previous ones, it has been 
found out that CRP levels in the patient were higher than in the control group 
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levels. There was higher CRP level in the patients whose clinical health was 
poor and had high Stroke Severity Scale. 
 Another study conducted by Mitchell SV Elkind et al also showed that 
levels of hs-CRP are higher in stroke patients than in stroke-free subjects101. 
Levels of inflammatory biomarkers associated with atherosclerosis, including 
hs-CRP, appear to be stable for at least 28 days after first ischemic stroke 
This study also found an association of post-stroke levels of hs-CRP with 
smoking and stroke severity. 
 Muir KW et al in his study found that hs-CRP levels above 10.1mg/L 
when measured within 72 hours of stroke predicted mortality over 4 years102. 
Others found that the measurement of CRP at 24 or 48 hours, but not at 
admission, also predicted outcome99. In one study, hs-CRP levels  ≥ 15 mg/L 
at discharge were associated with occurrence of a new vascular event or death 
at 1 year96. hs-CRP levels in the highest quintile measured at least 3 months 
after a first ischemic stroke or TIA were associated with an increased risk of 
subsequent stroke or MI in another study . 
 Another study was conducted by Yusuf Tamam et al to show the 
changes in plasma levels of six APPs (i.e., haptoglobin, ceruloplasmin,  
hs-CRP, fibrinogen, complement 3 and complement 4 during the first 10 days 
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after acute ischemic stroke. He concluded that the peak levels of APPs were 
higher in the AIS group than the control group (p < 0.0001)1. After stroke,  
hs-CRP, C3 and fibrinogen reached their highest values on the third day. The 
plasma levels of hs-CRP correlated positively with other five APPs studied  
(p < 0.05). His findings supported the importance of inflammatory processes 
after stroke. He suggested that the differences in levels of APPs could be used 
in predicting the outcome of ischemic stroke patient. 
 A population-based study of 476 people who had experienced their 
first ischemic stroke was undertaken to assess whether levels of lipoprotein-
associated phospholipase A2 (LP-PLA2) and high sensitivity C-reactive 
protein could predict the risk of another stroke, vascular events, and death 
over the next 4 years102. During follow-up, people in the highest quartile of 
hs-CRP levels (≥ 31.2 mg/l) had double the risk of death after a stroke 
compared with people in the lowest quartile, but were no more likely to 
experience another stroke. Levels of hs-CRP were also significantly linked to 
initial stroke severity. Because stroke severity is also strongly associated with 
mortality after stroke they concluded that hs-CRP is also associated with 
mortality. Because levels of hs-CRP remained independently linked to 
mortality after accounting for stroke severity, they added that this marker 
may provide additional complementary prognostic information. 
 31
 Elevated hs-CRP level are shown to be strongly associated with the 
extent of the atherosclerosis in the carotid arteries. The relationship between 
the increased serum hs-CRP levels and the atherosclerosis in the carotid 
arteries was found to be independent from the other known risk factors for 
the atherosclerosis. 
 Higher CRP concentration was an independent predictor of mortality 
together with age and the severity of the stroke on the National Institute of 
Health Stroke Scale (Muir K. W. et al., 1999)64. In  the same study, it was 
proposed that the CRP concentration was an   independent predictor of the 
survival after the ischemic stroke which was consistent with the role of the 
inflammation in acute ischemic stroke, as well as with the hypothesis that 
elevated CRP might predict the future cardiovascular mortality. Other studies 
also showed the association between the increased levels of CRP with a 
worse outcome in patients with ischemic stroke103 . Moreover in one study 
conducted in an elderly population without preexisting stroke, it has been  
demonstrated that elevated CRP concentration was an independent risk  
factor for future ischemic stroke over 10 years of follow-up104 . 
 CRP formerly considered solely an excellent biomarker of 
inflammation, is now viewed as a direct contributor in atherosclerosis. Recent 
evidences have emerged implicating CRP directly in atherogenesis. CRP has 
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been found in human atherosclerotic plaque and CRP has been shown to 
cause endothelial cell dysfunction, oxidant stress and intimal hypertrophy in 
experimental models. 
 It must be stressed that CRP, because of its analytical and biological 
properties and the large amount of available data, is the only inflammatory 
marker accepted for clinical use. hs-CRP not only predicts future 
cardiovascular events but can also be used to target therapeutic interventions. 
 Levels of hs-CRP < 1, 1 -3 and >3 mg/L correspond to lower, 
moderate and higher risk of cardiovascular events at all levels of Framingham 
Risk Score and at all levels of metabolic syndrome.  
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MATERIALS  AND METHODS  
Setting: 
Medical ward , Govt. Kilpauk Medical College, Chennai. 
Study design: 
Prospective hospital based study. 
Period of study: 
January 2008 to June 2008 
Inclusion criteria: 
1. All patients who presented within 48 hours of onset of stroke and who 
gave informed consent to participate in the study were included. 
Exclusion criteria: 
1. Subarachnoid haemorrhage, subdural haemorrhage and intracerebral 
haemorrhage were excluded with the aid of CT scan. 
2. Patients above 70 years of age were excluded. 
3. Patients with evidence of active infection and neoplastic conditions at    
the time of study were excluded. 
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4. Patients with rheumatic heart disease and collagen vascular disease 
were excluded. 
5. Patients who were actively smoking at the time of  study were 
excluded. 
6. Patients with previous history of transient ischemic attack or reversible 
ischemic neurological deficit were excluded. 
Study method: 
 A total of 50 patients who presented with acute ischemic stroke were 
enrolled into the study. That the stroke was an ischemic one was confirmed 
by CT scan. As soon as the patients were admitted within  48 hours of onset 
of stroke, serum samples were taken for hs-CRP estimation. Serum hs-CRP 
levels were also estimated in fifty normal patients (without any evidence of 
acute infection, neoplasm, rheumatic heart disease, collagen vascular disease, 
hypertension, DM, IHD) and was found to be within normal limits. 
 Standard guidelines for the treatment of acute ischemic stroke were 
followed. None of the patients received any thrombolytic treatment. They 
were treated only with antiedema measures and antiplatelets such as aspirin 
alone and with good nursing care and physiotherapy. 
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 The patients were reviewed after 4 weeks after onset of stroke and 
were stratified using the Glasgow Outcome Scale (GOS). The serum hs-CRP 
level was correlated with the functional recovery of patients after 4 weeks 
using the GOS. Patients with score of 4 and 5 were included in the good 
outcome and patients with score of 1, 2, 3 were included in the poor outcome 
cateogory.  
Definitions followed in the Study:  
1. Stroke  
 Stroke (as defined by WHO) was defined as rapidly developing clinical 
signs of focal or global (for patients in coma) neurological deficit lasting 
more than 48 hours or leading to death with no apparent cause other than 
vascular origin. 
2. hs-CRP: 
 Cut off value for hs-CRP for assessing the prognosis of stroke in this 
study was taken as  ≥ 10.1 mg/L and  the serum hs-CRP level was correlated 
with the functional recovery of patients after 4 weeks using the GOS. This 
was based on a study  by   Muir KW et al who found that hs-CRP levels 
above 10.1mg/L when measured within 72 hours of stroke predicted 
mortality over 4 years102. 
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3. GOS: 
 The GOS was utilized to assess the functional outcome and residual 
neurological deficit. The GOS has frequently been used  in trials involving 
stroke and brain injuries. It is a well validated scale with good interobserver 
agreement. 
GLASGOW OUTCOME SCALE (GOS)105,106: 
1 -  indicates death 
2 -   a vegetative state (the patient is unable to interact with the 
 environment) 
3 -   severe disability (the patient is unable to live independently but can 
 follow commands) 
4 -   moderate disability (the patient is capable of living independently but 
unable to return to work or school) 
5 -     mild or no disability (the patient is able to to return to work or school) 
 Favourable outcome was defined as a score of 4 or 5 and unfavourable 
outcome as a score of 1, 2 , or 3. 
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4. Hypertension: 
 Hypertension in this study was taken as BP ≥ 140/90 mmHg as per 
JNC VII. 
MEASUREMENT OF hs-CRP 
 The Quantia CRP-US (from Tulip Diagnostics Pvt. Ltd) was used for 
the measurement of hs-CRP. Quantia CRP is a turbidimetric immunoassay 
for ultrasensitive determination of CRP in human serum and is based on the 
principle of agglutination reaction .  The test specimen is mixed with quantia 
CRP US latex reagent and activation buffer and allowed to react.  Presence of 
CRP in the test specimen results in the formation of an insoluble complex 
producing a turbidity, which is measured at wavelength between 505-578 nm.  
The increase in turbidity corresponds to the concentration of CRP in the test 
specimen.   
Test procedure: 
 400 microlitre of quantia CRP US activation buffer (R1) was pipetted 
out and added to 100 microlitre of Quantia CRP US latex reagent (R2) in the 
measuring cuvette. It was mixed well and incubated for 5 minutes.   
5 microlitre of test specimen was added and mixed gently.  Absorbance (A1) 
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was read exactly at 10 seconds and absorbance (A2) was read again at the end 
of exactly  4 minutes.  ∆A (A2-A1) for test specimen was calculated.  
∆A gives the CRP concentration (‘C’)  of the test specimen.   
 The CRP concentration C was multiplied with the dilution factor (F) of 
the test specimen for obtaining the concentration of CRP in  the test  
specimen. 
Concentration of CRP in  the test specimen in  mg/dl=C x F, 
             ( where F is the dilution factor of the test specimen)   
 The quantia CRP US reagent has been designed to measure CRP 
concentrations in the range of 0.015-1.0 mg/dl and is linear within the 
measuring range. 
Statistical Analysis: 
The statistical methods used for analysis were 
1. Chi- Square test 
2. Sensitivity/Speccificity test 
 All analysis were done using Windows-based SPSS stastistical 
package (Version 11.5). 
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RESULTS AND ANALYSIS 
Total number of subjects included in the study  = 50 
Number of males      =24(48%) 
Number of females     =26(52%) 
 
Table 2: Age of individuals 
 
 Number of    
Cases 
Mean SD Std. Error 
Mean 
Age 50 60.32 7.44350 1.05267 
 
Mean age of individuals studied  =60.32 yrs ± 7.44 
 
Table 3: Time of sample collection 
 
 
Mean time of sample collection was 13.28 hours ± 9.96 
 
 Number of 
Cases 
Mean SD Std. Error 
Mean 
Time of 
collection 
50 13.28 9.95713 1.40815 
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Table 4:  CRP and S. Cholesterol levels 
 
95% Confidence 
Interval of the 
difference 
S.No Marker No. 
of 
cases
Mean SD Std. 
Error 
Mean 
Lower Upper 
1. S. Cholesterol 50 220.72 47.88935 6.77258 207.11 234.33 
2. S. hs-CRP 50 33.9023 31.56425 4.46386 24.9318 42.8728
 
Mean serum cholesterol level in these patients was 220.72 mg/dL 
Mean hs-CRP level was 33.9023 mg/L 
hs-CRP Vs Age group: 
 Out of the 14% of cases between the age group of 45-50 years, 2% had 
CRP values < 10.1 mg/L and 12% had CRP values ≥ 10.1 mg/L.  
 Out of the 12% of cases between the age group of 51-55 years , 6% 
had CRP values < 10.1 mg/L and 6% had CRP values ≥ 10.1 mg/L. 
 Between the age group of 56-60 years, 12% has CRP values  
< 10.1 mg/L and another 12% had CRP values than ≥ 10.1 mg/L. 
  Between the age group of 61-65 years, 2 cases (4%) has CRP values  
< 10 .1 mg / L and 8 cases (16%) had CRP ≥ 10.1 mg/L. 
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 Between the age group of 66-70 years, 3 cases (6%) had CRP values < 
10.1 mg /Land 12 cases (24%) had CRP values  than ≥ 10.1 mg/L. 
Table 5: hs-CRP vs Age group 
hs-CRP (mg/L) Age group (yrs) 
< 10.1 ≥ 10.1 
Total 
 
45-50 1(2%) 6(12%) 7(14%) 
51-55 3(6%) 3(6%) 6( 12%) 
56-60 6(12%) 6(12%) 12( 24%) 
61-65 2(4%) 8(16%) 10(20%) 
66-70 3(6%) 12(24%) 15( 30%) 
Total 15(30%) 35(70%) 50(100%) 
 
P=0.245      NOT SIGNIFICANT 
 The correlation between age and hs-CRP levels was not statistically 
significant.  
hs-CRP Vs Sex: 
 Out of the 24 males(48%) included in the study, 10% had CRP  
< 10.1 mg/L and 38% had CRP males had CRP ≥ 10.1 mg/L. 
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 Out of the 26 females(52%) included in the study, 20% had CRP 
values < 10 .1 mg / Land 32% had CRP ≥ 10.1 mg/L. 
Table 6: hs-CRP Vs Sex 
hs-CRP (mg/L) Sex 
< 10.1 ≥ 10.1 
Total 
 
Male 5(10%) 19(38%) 24(48%) 
Female 10(20%) 16(32%) 26(52%) 
Total 15(30%) 35(70%) 50(100%) 
 
P=0.174     NOT SIGNIFICANT 
 The correlation between sex and hs-CRP levels was not statistically 
significant.  
hs-CRP Vs Smokers: 
 The CRP profile in both smokers and non-smokers was studied. 42% 
were smokers. Out of them, 8% had CRP values < 10.1 mg/L and 34% had 
CRP values  ≥ 10.1 mg/L 
 Out of the 29 non smokers (58%), 22%  had CRP values < 10.1 mg/L 
and 36% had CRP values ≥ 10.1mg/L. 
 43
Table 7: hs-CRP Vs Smokers 
hs-CRP (mg/L) Smoker 
< 10.1 ≥ 10.1 
Total 
 
Yes 4(8%) 17(34%) 21(42%) 
No 11(22%) 18(36%) 29(58%) 
Total 15(30%) 35(70%) 50(100%) 
 
P= 0.215     NOT SIGNIFICANT      
 The correlation between smokers and hs-CRP levels was not 
statistically significant.  
hs-CRP Vs Alcoholics: 
 The hs-CRP profile of both alcoholics and non-alcoholics was studied. 
38% were  alcoholics . Among them, 8% had CRP < 10.1 mg/L.  30% had 
CRP  ≥ 10.1 mg/L. Out of the 62% non-alcoholics in the study, 22%  had 
CRP <  10.1 mg/L and 40% had CRP ≥ 10.1 mg/L. 
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Table 8:  hs-CRP Vs Alcoholics 
hs-CRP (mg/L) Alcoholic 
< 10.1 ≥ 10.1 
Total 
 
Yes 4(8%) 15(30%) 19(38%) 
No 11(22%) 20(40%) 31(62%) 
Total 15(30%) 35(70%) 50(100%) 
 
P=0.351     NOT SIGNIFICANT      
 The correlation between alcoholics and hs-CRP levels was not 
statistically  significant.  
hs-CRP Vs Hypertension: 
 The CRP profile in hypertensives was studied. 60% were hypertensives 
in the study group. 10% had CRP < 10.1 mg/L and 50% had CRP values  
≥ 10.1 mg/L. 
 Out of the 20 non-hypertensives(40%), 20% had CRP < 10.1 mg/L and 
another 20% had CRP  ≥ 10.1 mg/L. 
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Table 9: hs-CRP Vs Hypertension 
hs-CRP (mg/L) Hypertension 
< 10.1 ≥ 10.1 
Total 
 
Yes 5(10%) 25(50%) 30(60%) 
No 10(20%) 10(20%) 20(40%) 
Total 15(30%) 35(70%) 50(100%) 
 
P=0.025      SIGNIFICANT      
 Thus the correlation between hs-CRP levels and hypertension was 
found to be statistically significant. 
hs-CRP Vs Diabetics: 
 The CRP profile in both diabetics and non-diabetics was studied. 40% 
were diabetics in the study group. 8% had CRP values < 10.1 mg/L and 32% 
had CRP > 10.1 mg/L. 
 Out of the 30 non-diabetics (60%), 22%  had CRP < 10.1 mg/L and 
38%  had CRP > 10.1 mg/L. 
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Table 10: hs-CRP Vs Diabetics 
hs-CRP (mg/L) Diabetes 
< 10.1 ≥ 10.1 
Total 
 
Yes 4(8%) 16(32%) 20(40%) 
No 11(22%) 19(38%) 30(60%) 
Total 15(30%) 35(70%) 50(100%) 
 
P=0.0345         NOT SIGNIFICANT               
 Thus the correlation between hs-CRP levels and diabetes was not 
statistically significant. 
hs-CRP Vs IHD: 
 The CRP profile was studied among both IHD and non-IHD cases. 
18% of the total cases were found to have IHD. Of that only 2% had CRP  
< 10.1 mg/L and 16% had CRP ≥ 10.1 mg/L.  
 Out of the remaining 82% non-IHD patients, 28% had CRP < 10.1 
mg/L and 54% had CRP > 10.1 mg/L. 
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Table 11: hs-CRP Vs IHD 
hs-CRP (mg/L) IHD 
< 10.0 >10.1 
Total 
 
Yes 1(2%) 8(16%) 9(18%) 
No 14(28%) 27(54%) 41(82%) 
Total 15(30%) 35(70%) 50(100%) 
 
P=0.247                     NOT SIGNIFICANT               
 Thus the correlation between hs-CRP levels and IHD was not 
statistically significant. 
hs-CRP Vs GOS Score: 
 The serum hs-CRP levels were correlated with the functional outcome 
of the patient after 4 weeks with the help of Glasgow Outcome Scale (GOS). 
 All the patients with GOS score of 1, 2 and 3 (64%) had CRP values  
> 10.1 mg/L. 4% in this study group died. 
 Out of the 20% with GOS score of 4, 14% had CRP < 10.1 mg/L and 
6% had CRP > 10.1 mg/L. 
All the 16% cases with GOS score of 5 had CRP levels < 10.1 mg/L.  
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Table 12: hs-CRP Vs GOS Score 
hs-CRP (mg/L) GOS 
< 10.1 >10.1 
Total 
 
1 0(0%) 2(4%) 2(4%) 
2 0(0%) 13(26%) 13(26%) 
3 0(0%) 17(34%) 17(34%) 
4 7(14%) 3(6%) 10(20%) 
5 8(16%) 0(0%) 8(16%) 
Total 15(30%) 35(70%) 50(100%) 
 
hs-CRP Vs GOS Group: 
 Out of the 34% cases with GOS score of 4 or 5, i.e those with 
favourable outcome, 30% had CRP < 10.1 mg/L and 4% had CRP > 10.1 
mg/L.  
 All the remaining 66% cases with GOS score of 1, 2 or 3, (i.e 
unfavourable outcome) had hs-CRP > 10.1 mg/L. 
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Table 13: hs-CRP Vs GOS Group 
hs-CRP (mg/L) GOS group 
< 10.1 > 10.1 
Total 
 
Favourable 15(30%) 2(4%) 17(34%) 
Unfavourable 0(0%) 33(66%) 33(66%) 
Total 15(30%) 35(70%) 50(100%) 
 
P= 0.000              SIGNIFICANT     
 Thus there was significant statistical correlation between hs-CRP 
levels and functional outcome of the patient at the end of 4 weeks based on 
GOS score. 
SENSITIVITY/ SPECIFICITY TEST FOR hs-CRP: 
Table 14:  Sensitivity/ Specificity Test for hs-CRP 
Parameter Estimate Lower - Upper 95% 
CIs 
Sensitivity 100% (89.57, 100) 
Specificity 88.24% (65.66, 96.71) 
Positive Predictive 
Value 94.29% (81.39, 98.42) 
Negative Predictive 
Value 100% (79.61, 100) 
Diagnostic Accuracy 96% (86.54, 98.9) 
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 Thus hs-CRP is 100% sensitive and 88.24% specific as a prognostic 
tool in acute ischemic stroke. hs-CRP has a diagnostic  accuracy of 96% in 
patients with acute ischemic stroke.  
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DISCUSSION 
 The correlation between hs-CRP levels measured within 48 hours of 
onset of stroke to that of the functional outcome of the patient at the end of  
4 weeks (using GOS) was carried out.  
 Out of the 50 cases enrolled in the study, 35 cases (70%) had CRP 
values > 10.1 mg/L and 15 cases (30%) had CRP < 10.1 mg/L. 
 Out of the 35 cases with CRP > 10.1 mg/L, 4% had GOS score of  
1, 26% cases had GOS score of 2, 34% cases had GOS score of 3. 
 On the other hand, of the remaining 15 cases with CRP < 10.1 mg/L, 
none had a GOS score of 1, 2 or 3. 14% cases had a GOS score of 4 and 16% 
cases had a GOS score of 5. 
 Out of the 50 patients, 2 died. Both of them had very high hs-CRP 
levels. Thus patients with CRP levels < 10.1 mg/L had a relatively favourable 
outcome (GOS score of 1, 2 or 3) when compared to patients with levels  
> 10.1 mg/L (GOS score of 4 and 5). 
 So, in our study, the correlation between hs-CRP levels within  
48 hours of onset of ischemic stroke and the prognosis of the cases at the end 
of 4 weeks was statistically significant, the p value for hs-CRP being 0.000. 
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 This is consistent with the various studies conducted using hs-CRP as a 
prognostic indicator of acute ischemic stroke. 
Table 15: Studies conducted using hs-CRP as a prognostic indicator 
S. No Study Year 
1.  Di Napoli4,78,96 2001, 2002, 2005 
2.  Yusuf Tamam et al1 2005 
3.  Muir KW, Weir CJ, Alwar W et al64 1999 
4.  Mitchell S V Elkind et al101 2006 
5.  Ufuk Emre et al100 2007 
6.  Winbeck K et al99 2002 
7.  Kocer A et al98  2005 
8.  Rost N S et al103 2001 
9.  Cao J J et al104 2003 
 
 The correlation of hs-CRP levels with age and gender was studied. 
There was no statistically significant correlation between age and gender of 
the patient with the hs-CRP levels. This may be because of the small sample 
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size of our study group. But in a study conducted by So Yeon Ryu et al82 in 
2005, age had an independent association with plasma hs-CRP whereas 
gender showed no significant association with plasma hs-CRP. Also another 
study conducted by Rohde Lep et al81 in 1999 concluded that hs-CRP levels 
were statistically significant with age, number of cigarettes smoked per day, 
BP, total cholesterol. 
 In our study, smoking and alcohol had no statistical significance with 
hs-CRP levels. This is in contrast to a study conducted by So Yeon Ryu et 
al82 in 2005, where smoking had a significant correlation with plasma hs-CRP 
levels. Smoking is well supposed to give chemical and oxidative stimuli to 
the cardiovascular system and cause inflammation. The same study also 
reported that moderate alcohol consumption reduces circulating hs-CRP. 
Moderate alcohol consumption has anti-inflammatory effects. The 
mechanism causing moderate alcohol to decrease CRP levels needs further 
investigation. It involves nuclear factor (NF) – κB (Blanco – Colio et al 
2000)107. NF-κB is a redox sensitive transcription factor which activates 
geans involved in the immune, inflammatory or acute phase response, such as 
cytokines IL – 668 and TNF - α83 which regulates CRP production by liver. 
Another study conducted by M. Averina et al92 in 2003 and Chrysohoou et 
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al93 in 2003 showed a U-shaped association between hs-CRP and total alcohol 
intake.  
 In our study, total serum cholesterol did not have statistically 
significant correlation with hs-CRP levels. This is in contrast to a study 
conducted by So Yeon Ryu et al82 in 2005. A limitation of our study was that 
only total serum cholesterol was estimated  and not the complete lipid profile. 
 Our study showed a statistically significant correlation between high 
BP and hs-CRP. This is consistent with the study conducted by So Yeon Ryu 
et al82 in 2005 and Blackburn R et al88 in 2001. 
 Diabetes had no statistical significance with hs-CRP in our study. This 
is in contrast to many of the previous studies. This may be because of the 
small sample size and also because of the fact that our study included only 
acute ischemic stroke patients;  it was not done exclusively on diabetic 
subjects. 
 55
Table 16: Studies showing significant correlation between  
hs-CRP levels  and DM 
S.No Study Year 
1.  Blackburn R. et al88 2001 
2.  Minna Soinio et al95 2006 
3.  So Yeon Ryu et al82 2005 
 
 Our study also did not show a statistically significant correlation 
between IHD and hs-CRP levels. This is in contrast to many of the previous 
studies. This may be because our study included only ischemic stroke 
patients, it did not include IHD cases without stroke.  
Table 17: Studies showing significant correlation  
between hs-CRP levels  and IHD 
S.No Study Year 
1 Liuzzo et al21 1994 
2 Ferreiros et al27 1999 
3 winter et al26 1999 
4 Rasouli Mehdi et al94 2006 
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 The major difference between our study and those of other studies 
mentioned above was that our study involved only hs-CRP levels and not 
other acute phase reactants like fibrinogens.  Also, in our study we assessed 
the outcome of patients with acute ischemic stroke at the end of four weeks 
and not at the end of one year.  Also, we measured the CRP levels only 
within 48 after the onset of ischemic stroke and not at the end of four weeks 
or at the time of discharge. This was because of the cost involved in the 
measurement of hs-CRP. The other reason, why our study did not have 
significant correlation with age, sex, DM, IHD was that our study sample size 
was very small. 
 The prognostic importance of the 48-hour concentration of CRP may 
be partly related to the extent of ischemic necrosis and partly to the unknown 
individual determinants of the intensity of the acute phase reactants.  CRP is a 
very vital indicator of the inflammatory states during the acute phase of an 
ischemic stroke. 
 Knowledge  of the prognostic influence of the levels of CRP in the 
outcome of stroke of atherothrombotic etiology helps the clinician to offer 
realistic expectations to the families of stroke victims. 
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 Thus, CRP can be routinely measured for all stroke patients , as it has 
been found to provide a statistically significant level of prognostic 
information as to the eventual outcome of stroke both in short term such as in 
our study and also over a longterm as was shown in the study by DiNapoli  -
et-al 4,78,96. 
 Also, CRP has a direct relationship with other cardiovascular risk 
factors, like smoking, alcohol consumption, hypertension, diabetes and 
cholesterol. Thus  CRP levels may be a marker for preclinical cardiovascular 
disease. 
 As CRP was found to be an independent risk indicator of further 
cardiovascular and neurovascular events as shown by the subset of 
Framingham study, routine CRP screening of  susceptible population like 
chronic smokers and sibilings and first degree relatives of patients with IHD 
and stroke may prove a valuable indicator for predicting future 
athreothrombotic events and then it can be assessed as a routine indicator for 
aspirin prophylaxis. Thus CRP measurements may be helpful in grading 
patients into high risk and low risk category for predicting future 
cardiovascular and neurovascular events.  
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CONCLUSION 
• Patients with elevated hs-CRP had a poorer outcome when compared 
to patients with lower levels of CRP, four weeks after the onset of 
ischemic stroke. 
• hs-CRP levels showed statistically significant elevation in patients 
 with high blood pressure. 
• hs-CRP levels had no significant correlation with age or gender. 
• hs-CRP did not show a statistically significant correlation with 
 smoking or cholesterol intake. 
• There was no statistically significant correlation between hs-CRP 
levels and those with diabetes or IHD. 
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SUMMARY 
 
 
 This study was done to evaluate the predictive value of hs - CRP in 
relation to the ultimate functional outcome in first ever ischemic stroke after 
4 weeks and also to correlate the hs - CRP levels with various cardiovasclar 
risk factors. It was found that patients with elevated  
hs - CRP levels had a poorer outcome when compared to patients lower 
levels of hs - CRP, 4 weeks after the onset of ischemic stroke. This study also 
showed that hs - CRP levels were elevated in patients with high B.P.  
 Thus routine screening of susceptible populations like chronic 
smokers, alcoholics and first degree relatives of patients with IHD, stroke and 
DM may prove  a valuable indicator for predicting future  
cardiovascular and neurovascular events.  
 Thus hs - CRP measurements may be helpful in grading the patients 
into high risk and low risk category, for predicting future adverse 
atherothrombotic events and outcome. 
ABBREVIATIONS 
 
 
%    - Percentage  
APP              - Acute phase protein 
BP                - Blood pressure 
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